UK (Commonwealth Union) – The targeting of and enzymes and other proteins essential for biological processes by manipulation has been a major cornerstone in biotechnology, particularly animal and medical biotechnology. Scientists have created a novel molecule capable of destroying a presently undruggable cancer-causing protein and allowed scientists from across the globe to use it for their work absolutely free!
A molecule which can destroy a cancer-causing protein is presently available to labs across the globe through the access portal opnMe.com. ACBI2 – the molecule discovered together by the University of Dundee and the biopharmaceutical company Boehringer Ingelheim, has been made accessible for other researchers to implement in their own investigations.
The initiative hopes to gather the power and resources of global medical researchers to transform the lives of cancer patients by forming better treatments for them, who presently have insufficient options. The formation of the new molecule will pave the way for cancer researchers worldwide to speed up their research and gather deeper knowledge of the disease with the biology of cancer and other areas of high unfulfilled medical requirements.
ACBI2 is a significant step in the right direction in specific targeting and degradation of the protein SMARCA2, which has a vital role in gene regulation and has known involvement in the development of a variety of cancers. Degrading as opposed to inhibiting a target protein offers many benefits like more efficacious drug response with smaller doses, and more surgical intervention with possibly lower side effects and disease resistance.
Dr Will Farnaby, Collaboration Leader from the University of Dundee, Centre for Targeted Protein Degradation stated that this research is a significant breakthrough for the designing of molecules to target and eliminate cancer-causing proteins, highly selectively and as an oral therapy. “We expect the discovery of ACBI2 to provide a vital blueprint for the future discovery of targeted protein degradation drugs and act as a critical tool to understand SMARCA2 biology,” he said.
